# US 2010/0305095 A1 · Use of HPPD Inhibitors in the Treatment of Depression and/or Withdrawal Symptoms Associated with Addictive Drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0305095 A1
- Document ID: US20100305095A1
- Status: Published application
- Kind: A1
- Application number: 12/377,787
- Filed: 2006-08-18
- Published: 2010-12-02
- Earliest claimed: 2006-08-18
- Inventors: Kim Zachary Travis; John Posner
- Web page: https://patentgrep.com/patent/US20100305095A1

## CPC

- A61K 31/4412: having oxo groups directly attached to the heterocyclic ring
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/415: 1,2-Diazoles
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/42: Oxazoles
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/24: Antidepressants
- A61P 25/30: for treating abuse or dependence
- A61P 25/32: Alcohol-abuse
- A61P 25/34: Tobacco-abuse
- A61P 25/36: Opioid-abuse
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to, inter alia, the use of a compound capable of inhibiting 4-hydroxyphenylpyruvate dioxygenase (HPPD) in an animal in the manufacture of a medicament for use in the treatment and/or prevention of depression. The invention also provides for the use of a compound capable of inhibiting HPPD in an animal in the manufacture of a medicament for use in the treatment of the withdrawal symptoms associated with an addictive drug which causes dopamine dependant associative learning disorders in said animal. In a particular embodiment said HPPD inhibitor is selected from the group consisting of the compound depicted as compound 1; 2; and 3.22.

## Claims

### Claim 1

The use of at least one compound capable of inhibiting 4-hydroxyphenylpyruvate dioxygenase (HPPD) in an animal in the manufacture of a medicament for use in the treatment and/or prevention of depression.

### Claim 2 (depends on 1)

The use according to claim 1 wherein said medicament comprises a compound selected from the group consisting of: compound 1; 2; and 3.22.

### Claim 3 (depends on 1, 2)

The use according to claim 1 or claim 2 wherein said medicament comprises the compound depicted as compound 1.

### Claim 4

The use according to any one of the previous claims wherein said medicament comprises a selective serotonin reuptake inhibitor (SSRI) and/or a tricyclic antidepressant (tricyclic).

### Claim 5 (depends on 4)

The use according to claim 4 wherein said SSRI is selected from the group consisting of: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline or mixtures thereof and said tricyclic is selected from the group consisting of: amitriptyline, clomipramine, dosulepin, dothiepin, doxepin, maprotiline, mianserin, trazodone, trimipramine, amoxapine, imipramine, lofepramine, and nortriptyline or mixtures thereof.

### Claim 6

A kit comprising a pharmaceutically effective amount of a compound selected from the group consisting of: compound 1; 2; and 3.22 or a pharmaceutically acceptable salt thereof and a pharmaceutically effective amount of a selective serotonin reuptake inhibitor and/or a tricyclic antidepressant and a means for the delivery thereof to an animal.

### Claim 7

A pharmaceutical composition comprising as an active ingredient a pharmaceutically effective amount of a compound selected from the group consisting of compound 1; 2; and 3.22 or a pharmaceutically acceptable salt thereof and a pharmaceutically effective amount of a selective serotonin reuptake inhibitor and/or a tricyclic antidepressant together with a pharmaceutically acceptable diluent or carrier.

### Claim 8 (depends on 7)

A pharmaceutical composition according to claim 7 wherein said SSRI is selected from the group consisting of: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline or mixtures thereof and said tricyclic is selected from the group consisting of: amitriptyline, clomipramine, dosulepin, dothiepin, doxepin, maprotiline, mianserin, trazodone, trimipramine, amoxapine, imipramine, lofepramine, and nortriptyline or mixtures thereof.

### Claim 9

The use of at least one compound capable of inhibiting 4-hydroxyphenylpyruvate dioxygenase (HPPD) in an animal in the manufacture of a medicament for use in the treatment of the withdrawal symptoms associated with an addictive drug which causes dopamine dependant associative learning disorders in said animal.

### Claim 10 (depends on 9)

The use according to claim 9 wherein said addictive drug is a drug selected from the group consisting of: cocaine, amphetamine, opiate, nicotine, ethanol, tetrahydrocannabinol and phencyclidine.

### Claim 11 (depends on 10)

The use according to claim 10 wherein said medicament comprises a compound selected from the group depicted as compound 1; 2; and 3.22.

### Claim 12 (depends on 9, 10, 11)

The use according to any one of claims 9 to 11 wherein the medicament comprises a further compound which is also capable of inhibiting 4-hydroxyphenylpyruvate dioxygenase (HPPD) in an animal.

### Claim 13 (depends on 9, 10, 11, 12)

The use according to any one of claims 9 to 12 wherein said medicament comprises a nicotine replacement therapy.

### Claim 14 (depends on 9, 10, 11, 12, 13)

The use according to any one of claims 9 to 13 wherein said medicament comprises bupropion.

### Claim 15 (depends on 9, 10, 11, 12, 13, 14)

The use according to any one of claims 9 to 14 wherein said medicament is used in conjunction with a nicotine replacement therapy.

### Claim 16 (depends on 9, 10, 11, 12, 13, 14, 15)

The use according to any one of claims 9 to 15 wherein said medicament is used in conjunction with bupropion.

### Claim 17

A kit comprising a pharmaceutically effective amount of compound selected from the group consisting of: 1; 3.22; and 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically effective amount of a nicotine replacement therapy and/or bupropion and a means for the delivery thereof to an animal.

### Claim 18

A pharmaceutical composition comprising as an active ingredient a pharmaceutically effective amount of a compound selected from the group consisting of: compound 1; 3.22; and 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically effective amount of a nicotine replacement therapy and/or bupropion together with a pharmaceutically acceptable diluent or carrier.

### Claim 19 (depends on 7, 8, 18)

A pharmaceutical composition according to claim 7, 8 and 18 which is in a form suitable for oral or parenteral administration.

### Claim 20 (depends on 19)

A pharmaceutical composition according to claim 19 which is in palatable form suitable for oral administration selected from the group consisting of tablets; lozenges; hard capsules; aqueous suspensions; oily suspensions; emulsions; dispersible powders; dispersible granules; syrups and elixirs.

### Claim 21 (depends on 19, 20)

A pharmaceutical composition according to claim 19 or 20 which is intended for oral use and is in the form of hard or soft gelatin capsules.

### Claim 22 (depends on 19)

A pharmaceutical composition as claimed in claim 19 which is in a form suitable for parenteral administration.

### Claim 23 (depends on 7, 8, 18, 19, 20, 21, 22)

A method of treating and/or preventing depression comprising administering to an animal a pharmaceutically effective amount of a compound selected from the group consisting of: compound 1; 2; and 3.22 or a composition according to any one of claims 7, 8, 18 to 22.

### Claim 24 (depends on 7, 8, 18, 19, 20, 21, 22)

A method of treating an animal suffering from withdrawal symptoms resulting from addiction to a drug which is responsible for the development of dopamine dependant associative learning disorders in said animal comprising administering to said animal a pharmaceutically effective amount of a compound selected from the group consisting of: compound 1; 3.22; and 2 or a composition according to any one of claims 7, 8, 18 to 22.

### Claim 25 (depends on 23, 24)

A method according to claim 23 or 24 wherein said animal is a human being.
